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Summary The usefulness of post-operatively serial serum CA15-3 determination with CEA and TPA was
evaluated in a group of 285 breast cancer patients. In particular, the CAI5-3 sensitivity to 'early' diagnosis and
monitoring of the response to treatment of breast cancer relapses, was compared with those of the two other
markers in order to'define the most suitable association. Moreover, in a group of 169 non relapsed patients
with a prolonged follow-up (40±8 months; mean±s.d.) CA15-3 specificity was investigated.
During post-operative follow-up in 27 (10%) patients, distant metastases occurred. In most of them,
elevated values of one or more tumour markers were the first pathological sign and CA15-3, CEA and TPA
sensitivity to 'early' diagnosis of metastases were 46%, 7% and 63% respectively. When each tumour marker
was considered in combination, CA15-3-CEA-TPA association showed a higher sensitivity (87%) than both
CA15-3-TPA (83%) and the CEA-TPA (70%). Serum CA15-3 increase preceded the certain sign of metastases
2.7 ±2.6 months (mean ±s.d.). Shortly before appearance and during treatment of distant metastases, constant
elavation and/or progressive increase in serum CAl 5-3 values occurred in all evaluated patients except three in
whom isolated elevated values were found as well. In 24 (14%) of 169 non relapsed patients with prolonged
follow-up (40±8 months; mean±s.d.) high serum CA15-3 values occurred. In 16 of these 24 patients, an
isolated elevated value was found, while four (2.3%) or the eight remaining ones with constant elevation
and/or progressve increase were falsely suspected of metastases. In this group of non relapsed patients, chronic
liver failure, diabetes and/or hepatic steatosis were the reasons more commonly responsible for the CA15-3
increase. In metastatic patients, no organ-specificity was shown either by CA15-3 or by CEA and TPA. In
these patients serum TPA values showed the highest sensitivity and paralleled clinical and/or instrumental
signs better than the CA15-3 and even more than CEA values. These data indicate that in the post-operative
follow-up of breast cancer patients, TPA is the most useful tumour marker and TPA-CA15-3 the most suitable
association. Contemporaneous measurement of serum CEA levels only slightly increases sensitivity and
positive predictive value of TPA-CA15-3 combination.
In clinical practice, determination of the so-called tumour
markers proved most useful in the diagnosis of distant metas-
tases and in monitoring the response to treatment of relapsed
patients (Haagensen, 1982).
Most of them circulate in serum (Gorksy et al., 1976;
Humphrey et al., 1974; Maidment et al., 1981), but only
certain of the known markers are suitable for the particular
organ involved and the histological type of cancer. In fact
each type of cancer usually expresses few markers which
significantly increase at relapse or thereafter. According to
whether the tumour marker's increment occurs before or
soon after the confirmation of relapse by conventional means
(i.e. clinical and/or histological and/or radiological signs),
tumour marker measurement can be useful both for an 'ear-
lier' diagnosis of relapse and the monitoring of response to
treatment or only for the monitoring.
So far, most tumour markers have not shown such a high
sensitivity and specificity to be used alone; therefore various
associations must be considered. In breast cancer, carcino-
embryonic antigen (CEA) and tissue polypeptide antigen
(TPA) are two of the most commonly determined tumour
markers.
In our previous study (Nicolini et al., 1989) we showed
that their serial serum determinations with contemporaneous
urinary hydroxyproline-creatinine ratio (OHP/Cr) measure-
ment (the latter as a bone tissue marker) provide guidelines
for a rational post-operative follow-up of breast cancer
patients. In fact, in most patients, high values of these
tumour markers were the first sign of relapse; furthermore,
they are easily repeatable and harmless examinations. More
recently, a new antigenic determinant defined by two mono-
clonal antibodies (115 D8 and DF3), has been found in
blood of patients with breast cancer. Thus, an immunoradio-
metric assay (IRMA), has been developed with these two
MAbs to measure the breast cancer associated antigen 115
D8/DF3 (CA15-3).
So far, the collected data also suggest that this tumour
marker is not useful for the diagnosis of the primary tumour
(Gion et al., 1986; Schmidt-Rhode et al., 1987). Moreover,
they indicate that this new marker correlates with the stage
of disease and in metastatic patients with the response to
treatment (Colomer et al., 1986; Hilkens et al., 1984; Omar et
al., 1988).
Nevertheless, there are insufficient data to define whether
this marker is advisable for use with or in place of the more
commonly used markers for the post-operative follow-up of
breast cancer patients.
In our Center since 1985, all breast cancer patients follow-
ed-up with CEA and TPA have also been followed with
serial serum CA15-3 determinations.
The prolonged period of observation and the large number
of patients studied allowed us to evaluate the usefulness of
serum CA15-3 measurement in 'early diagnosis' and in the
monitoring of response to therapy of breast cancer relapses.
Moreover, these findings were compared with those of CEA
and TPA to define the most suitable association of these
three tumour markers.
Materials and methods
Patients
Since June 1985 until September 1989, 285 breast cancer
patients, aged 29 to 84 years, followed-up post-operatively
with serial determinations of CEA and TPA were also moni-
tored by serum CA15-3 measurement.
Ninety-five (33.3%) patients were premenopausal and the
post-operative axillary lymph-node involvement (N + ) was
found in 119 (42%). The mean follow-up was 32 ± 15
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months (mean + s.d.) and 30 patients withdrew from the
study.
On entering the study, only 17 patients showed any sign of
metastases. In four and 13 of these 17 patients, loco-regional
recurrences and distant metastases were found respectively.
In other 27 patients metastases occurred during the period of
follow-up.
In the N + patients the follow-up visits were at a 4-
monthly intervals and in the lymph-node negative patients
(N - ) every 6 months, due to better prognosis.
Each visit consisted of a clinical examination, an accurate
history and the routine laboratory examinations to investi-
gate whether benign disease might cause the increase of
tumour marker level.
Laboratory methods
Serum CEA, TPA and CA15-3 levels were measured in fast-
ing patients by radioimmunoassay (RIA) or immunoenzy-
matic assay (EIA) methods. CEA was measured by Lepetit
Lysophase RIA (Milano, Italy) and successively by Sorin
Biomedica (Saluggia, Italy) commercial kits; serum levels
>7 ng ml-' were considered elevated.
TPA was measured by Sangtec Medical (Bromma, Sweden)
commercial kit; serum levels initially >60 mU ml-' and suc-
cessively >85 mU ml-' were considered elevated.
Serum CA15-3 concentrations were determined by IRMA
(Cis International) commercial kit and 32 U ml-' was taken
as the cut-off level.
The CEA, TPA and CA15-3 within and between assay
variations were less than 6% and 9% respectively. When the
TPA cut off value was 60 mU ml-' its variation coefficients
increased to 10% and 15% respectively.
In the 241 patients without relapse, serum CEA, TPA and
CA15-3 determinations were performed 1374, 1350 and 1360
times respectively, while in the 44 patients with metastases
they were carried out 282, 283 and 276 times.
Sensitivity ofCA15-3, CEA, TPA in the 'early' diagnosis of
breast cancer metastases and in relapsedpatients
During the post-operative follow-up in patients without any
clinical sign of relapse and all three tumour markers within
the normal range, imaging techniques were performed at
regular intervals according to a fixed protocol reported pre-
viously (Nicolini et al., 1989).
Moreover, when any patient was suspected of relapse by
tumour markers or clinically, radiological examinations were
immediately carried out to confirm the suspicion and to
define the site of metastases.
Increase of markers were subdivided into: isolated elevated
value, constant elevation and progressive increase.
In particular, when an elevated value of one or more
tumour markers occurred, another sample was taken within 1
month. When the tumour marker's increase decreased to a
normal level after a high value, it was considered as isolated
elevated value. The tumour marker elevation was considered
progressive when a high value increased by > 30% in the
sample following the elevation. Otherwise, these two high
values were regarded as constant elevation.
In the 'early' diagnosis of breast cancer metastases, true
positive patients were considered when one or more tumour
markers increased simultaneously or preceded the clinical and
imaging signs of metastases, and the following sample con-
firmed the marker increase. As to sensitivity of the 27
patients who relapsed during the follow-up, for CEA and
TPA it was evaluated in them all, while for CAl 5-3 it was
evaluated in 24.
Sensitivity of CA15-3, CEA, TPA was also evaluated in 40
relapsed patients which included those where tumour
markers had not been the first pathological finding or who
had started monitoring with tumour markers after clinical
and/or radiological signs of distant metastases.
Among these, we considered true positives those who dur-
ing a follow-up longer than 1 year and in more than two
samples showed high tumour marker levels probably due to
metastatic disease. We assumed that as sensitivity in relapsed
patients and it allowed us to investigate the frequency of
expression of the three tumour markers.
CA15-3, CEA, TPA specificity in thepost-operativefollow-up
In a group of 169 patients without any clinical and radio-
logical signs of relapse and followed-up longer than 24
months (40 + 8; mean + s.d.), constant elevation or progres-
sive increase in serum CEA, TPA and CA15-3 levels were
considered falsely positive results when not explained by
concomitant benign disease. In fact, data from our previous
work (Nicolini et al., 1989), showed that an isolated elevated
tumour marker level hardly ever suggests breast cancer meta-
stases.
Evaluation ofCA15-3, CEA and TPA sensitivityfor
monitoring the response to therapy in metastatic patients
CA15-3, CEA and TPA sensitivity for monitoring the re-
sponse to therapy was investigated in the group of 40
relapsed patients. In all evaluable patients, clinical and
radiological signs were compared with mean serum levels of
tumour markers at the relapse, 3 to 6 and 7 to 12 months
after the beginning of treatment (D = percentage of difference
with mean serum levels at relapse). Only three conditions
were considered: progression (slight and strong), remission
(partial and complete) and stable disease.
Criteria to define variations of the clinical picture were as
follows: slightly progressive disease (appearance or mild
worsening of symptoms likely related to the relapse with or
without corresponding radiological signs) strongly progres-
sive disease (overall worsening of clinical picture with corre-
sponding radiological signs, i.e. 50% or greater increase in
the measurable lesions or appearance of new lesions) partial
response (disappearance or mild improvement of symptoms
likely releated to the relapse with or without corresponding
radiological signs) complete response (overall improvement
of clinical picture with corresponding radiological signs, i.e.
50% of greater reduction in the measurable lesions and no
appearance or new lesions) stable disease (no variation of
symptoms and radiological signs). Patients with progressive
disease evaluated in relation to serum CA15-3, CEA and
TPA levels were 11, 10, 20, those with remission 6, 5, 8 and
those with stable disease were 4, 3, 8 respectively.
Results
Sensitivity ofCA15-3, CEA, TPA in the 'early' diagnosis of
breast cancer metastases and in relapsedpatients
In 21 breast cancer patients who relapsed during the follow-
up serum levels increase of one or more tumour markers
preceded the clinical and/or radiological signs of distant
metastases. The highest sensitivity was shown by TPA alone
and the CA15-3-CEA-TPA combination (Table I).
In particular, in 11 patients, high serum CAl5-3 values
were the first pathological finding ofrelapse. In nine ofthem,
the time elapsed between CA15-3 increase and the clinical
Table I Sensitivity, specificity andpositive predictive valueofCA15-3,
CEA, TPA in the 'early' diagnosis of breast cancer metastases
Sensitivity Specificity Positivepredictive
Markers % % value %
CA15-3 46 98 78
CEA 7 99 67
TPA 63 98 85
CA15-3 + CEA 50 98 75
CA15-3 + TPA 83 96 77
CEA + TPA 70 98 86
CA15-3 + CEA + TPA 87 96 78156 A. NICOLINI et al.
and/or radiological signs of distant metastases was 2.7 ± 2.6
months (mean ± s.d.), while in the two others receiving tamo-
xifen adjuvant treatment it was 18 and 24 months respec-
tively. In 17 patients, high serum TPA values were the first
sign of distant metastases. In 15 of them, the time elapsed
between TPA increase and the certain signs of relapse was
3.4±2.7 months (mean ± s.d.) while in the two remaining
patients receiving tamoxifen it was 18 and 20 months respec-
tively.
With regard to CEA, high serum values occurred contem-
poraneously or preceded 3 months respectively the clinical
and radiological signs of distant metastases in only two
patients. High serum CA15-3, CEA and TPA values were
found in 21 (52%), 18 (45%) and 36 (90%) respectively of
the 40 relapsed patients evaluated. When three tumour
markers were considered in combination, the sensitivity of
CA15-3-CEA-TPA association was 95% that of CEA-TPA
and CA15-3-TPA combinations was 92%, whilst CA15-3-
CEA association showed only a 75% sensitivity.
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Unspecific increase andfalse positives ofCA15-3, CEA, TPA
The kind of increase and the reasons probably responsible
for the tumour marker increase in 169 non-relapsed breast
cancer patients with prolonged follow-up, are shown in Table
II.
When all increments were taken into account, isolated
elevated values of CA15-3, CEA and TPA occurred 18, 16,
109 times in 16 (9%), 14 (8%) and 77 (45%) patients respec-
tively. Constant elevation was found 13, 7, 69 times in seven
(4%), four (2.3%), 32 (19%) patients while progressive in-
crease 1, 0, 20 times in one (0.6%), 0, 14 (8%) subjects.
Nevertheless, the false positives, that is patients with constant
and/or progressive increase of tumour marker not explained
by concomitant benign pathology, were four (2.3%), one
(0.6%) and three (1.7%) for CA15-3, CEA and TPA respec-
tively. When they were considered in association, CEA-TPA
and CA15-3-CEA specificity was 98% while that of CA15-3-
TPA and CA15-3-CEA-TPA combinations decreased to 96%
(Table I).
CA15-3 increment before relapse andduring treatment of
metastatic patients. Site ofmetastases in the truepositives
Shortly before the appearance of distant metastases in all 12
evaluated patients, constant elevation and/or progressive in-
crease in serum CA15-3 values preceded clinical and/or
radiological signs of relapse; in three (25%) of them there
was concomitant benign pathology able to explain the
marker increase. The only patient who showed also an iso-
lated elevated value was on adjuvant tamoxifen treatment
and without benign disease.
During treatment of metastases in all 18 evaluated
patients, constant elevation and/or progressive increase
occurred. In five (28%) of these 18 patients there were con-
comitant reasons known to increase the marker's level. In
two (11%) patients showing also an isolated elevated value
no concomitant benign pathology was found.
Table III shows the site of metastases in patients with
elevated values of CA15-3, CEA and TPA. Bone, lung and
liver involvement occurred in 16 (76%), six (28%) and three
(14%) respectively in patients with an elevated CA15-3, in 12
(67%), five (28%) and four (22%) for CEA, in 27 (75%), ten
(28%) and seven (19%) for TPA.
Evaluation ofCA15-3, CEA and TPA sensitivity to monitor
the response to therapy in metastatic patients
In the patients with progressive disease the mean serum
CA15-3 (t ml-') values were 55.5, 98 and 157 at relapse, 3 to
6 and 7 to 12 months after beginning of therapy respectively.
At the same intervals in patients with remission and stable
disease they were 139, 100, 85.5 and 37.5, 47, 46 respectively.
As regards the mean serum CEA (ngml-') levels in progres-
sive disease they were 10.3, 28.7 and 38.3 at relapse and the
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Table III Site of metastases in patients with elevated serum CA15-3, CEA and TPA values
Pts Site ofrepetitions
evaluated
Marker n B L Li B-L L-Li B-Li B-L-Li P Br S
CA15-3 21 12 3 1 2 - 1 1 - - I
CEA 18 9 2 1 1 1 1 1 - - 2
TPA 36 19 4 1 3 1 3 2 1 1 1
Pts = patients; B = bone; L = lung; Li = liver; P = pleura; Br = brain; S = skin.
following intervals while in patients with remission and stable
disease they were 13.6, 11, 11 and 7.8, 8.1, 10.2 respectively.
The mean serum TPA (mU ml-') values in patients with
progression were 170, 277 and 491 at the fixed intervals,
while in those with remission and stable disease they were
251, 152, 59.1 and 113, 105 and 111 respectively. Therefore in
the progressive disease serum increase of three markers
occurred 3 to 6 (D = + 76.5%, + 179% and + 63% respec-
tively) and still more (D = + 183%, + 272% and + 188%
respectively) 7 to 12 months after relapse. In patients with
remission, all three markers decreased 3 to 6 months after the
appearance of metastases (D = - 28%, - 19% and - 39%
respectively). At the following interval CA15-3 and TPA
values further decreased (D = - 38% and - 76% respec-
tively) while mean serum CEA levels did not change.
In patients with stable disease, CA15-3 and CEA values
both at 3 to 6 (D = + 25.6% and + 3.8% respectively) and 7
to 12 months intervals (D = + 23% and + 30% respectively)
were higher than at relapse while at the same intervals serum
TPA levels slightly decreased (D =-7% and - 1.7%
respectively).
Discussion
In the 'early' diagnosis of breast cancer relapses, CA15-3
showed a sensitivity much higher than CEA and lower than
TPA (Table I). The mean interval between serum CA15-3
increase and the appearance of signs of distant metastases
was similar to those of TPA and CEA (2.7 ± 2.6 vs 3.4 ± 2
and 1.5 ± 2 months) respectively. This last result shows that
in most breast cancer patients, serum CA15-3 levels as with
CEA and TPA increase a few months before clinical and/or
radiological signs of distant metastases. Nevertheless, the
much longer interval (18 to 24 months) found for CAl 5-3 or
TPA in four patients receiving tamoxifen confirms earlier
data (Nicolini et al., 1989; Fisher et al., 1981; Henderson et
al., 1988; Palshof et al., 1980), in which in hormone-
responsive patients, 'early' or adjuvant treatment with tamox-
ifen significantly delays progression of disease and prolongs
the interval from tumour marker increase to the clinical
and/or radiological signs of relapse.
In nonrelapsed patients, isolated elevated value of all three
tumour markers occurred more often than constant elevation
and this type of increment more than progressive increase
(Table II). Moreover, most of these tumour marker increases
were concomitant with benign disease, in particular consis-
tent with previous data (Nicolini et al., 1989; Colomer et al.,
1986; Ruibal et al., 1986a, b), hepatic diseases (transient or
chronic liver failure, diabetes and/or hepatic steatosis) seem
to be the most commonly involved. Thus a very high speci-
ficity ranging from 96 to 99% was obtained both when three
tumour markers were considered alone and in association
(Table I).
In all metastatic patients with high serum CA15-3 values
before and during treatment constant elevation and/or pro-
gressive increase in this tumour marker were found and only
in three of them also isolated elevated value occurred. There-
fore it can be inferred that, as we reported for CEA and TPA
(Nicolini et al., 1989) mainly in patients without concomitant
benign disease, CA15-3 constant elevation or progressive in-
crease unlike isolated elevated value strongly suggest breast
cancer relapse.
In relapsed patients, TPA showed the highest sensitivity
(90%) while only in about half of them high CA15-3 and
CEA levels occurred. This indicates that most breast cancer
metastases produce TPA and only about half of them CA15-
3 and CEA.
In these patients, no organ specificity was shown either by
CAl5-3 or by CEA and TPA. In fact, when all sites of
metastases were considered, no significant difference was
found among the percentages of patients with high CA15-3
values and those with elevated CEA or TPA concentrations,
with regard to the frequency of the main target organs
involved (bone, lung, liver) (Table III). On the other hand,
each of the three tumour markers showed a higher percen-
tage in patients with bone metastases than that of patients
with lung involvement and the percentage was even less in
patients with liver metastases (Table III).
Serum TPA levels reflected the variations of metastatic
disease better than CA15-3 and CEA. In fact, when serum
values of the three markers were compared with the clinical
and/or radiological variations, in progressive disease at both
the evaluated intervals, the percentage of mean serum CEA
increase was higher than that of CA15-3 and TPA. Never-
theless, in patients with remission and stable disease mean
serum CEA values showed the lowest decrease (D = - 19%)
and the highest difference (D = + 30%) respectively. Better
correspondence was given by CA15-3 and even more by
TPA.
These findings are consistent with previous studies at least
as regards TPA and CEA (Luthgens & Schlegel, 1981; Skry-
ten et al., 1981; Biorklund, 1983; Quayle, 1982) and suggest
that TPA is related to tumoral proliferation while CA15-3
and CEA are tumour mass related antigens. In conclusion,
data from this study indicate that in the post-operative
follow-up ofbreast cancer patients, TPA is the most useful of
the three tumour markers and CA15-3 TPA is the most
suitable combination. In spite of a slight decrease of positive
predictive value in respect of the CEA-TPA combination
(77% vs 86%), CAl5-3 more significantly increased TPA
sensitivity in the 'early' diagnosis of breast cancer relapses
(Table I). Moreover, monitoring the response to therapy
serum CA15-3 levels showed better correspondence with the
clinical and radiological variations than the CEA levels.
Contemporaneous measurement of serum CEA levels only
slightly increases sensitivity and positive predictive value of
CA15-3-TPA association (Table I).
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